Mira Pharmaceuticals (MIRA) Non Operating Income (2024 - 2025)
Mira Pharmaceuticals (MIRA) posted Non Operating Income of -$158494.0 for Q4 2025, down 188.39% sequentially from $179312.0 in Q3 2025, and down 515.94% YoY from $38105.0 in Q4 2024.
Mira Pharmaceuticals (MIRA) Non Operating Income (2024 - 2025) Analysis & Trends
Mira Pharmaceuticals has reported Non Operating Income for 2 years, with the latest figure at -$158494.0 in Q4 2025.
- Quarterly Non Operating Income fell 515.94% year-over-year to -$158494.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $96675.0 (changed N/A YoY) and the FY2025 annual result came in at $50627.0, down 69.44% from the prior year.
- Non Operating Income eased to -$158494.0 in Q4 2025 per MIRA's latest filing, from $179312.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $179312.0 in Q3 2025 and troughed at -$158494.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -73.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 387.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Mira Pharmaceuticals | 18.47 Mn | 7.44 Mn | - | -158,494.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -158,494.00 |
| Sep 30, 2025 | 179,312.00 |
| Dec 31, 2024 | 38,105.00 |
| Sep 30, 2024 | 37,752.00 |